idronoxil
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2017 (NCT03307629)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase AKT2INHIBITOR
AKT2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05100628 | Phase 1 | Nov 15, 2021 | Noxopharm Limited |
| NCT04957290 | Phase 1/Phase 2 (Phase 2) | Oct 25, 2021 | Noxopharm Limited |
| NCT04555213 | Phase 1 | Sep 30, 2020 | Noxopharm Limited |
| NCT03780465 | Phase 1 | Mar 1, 2019 | Noxopharm Limited |
| NCT03307629 | Phase 1 | Nov 1, 2017 | Noxopharm Limited |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Noxopharm Limited | For profit | 5 | 5 | 2 | 2017 |
1 organizations
Page 1 / 1